Urotensin-II (U-II) is a peptide ligand, initially isolated from the neurosecretory system of the Goby fish (Gillichthys mirabilis). For many years it was thought that U-II does not exhibit significant effects in mammalian systems; a view quickly overturned when it was demonstrated that Goby U-II produces slow relaxation of mouse anococcygeus muscle, in addition to contraction of rat artery segments. In 1998, the cDNA encoding a U-II precursor was cloned in humans, unequivocally demonstrating its existence in mammalian species.The vasoconstriction it induces can cause or exacerbate hypertension, congestive heart failure, and coronary artery disease.
In fish, U-II is secreted at the back part of the spinal cord, in a neurosecretory center called uroneurapophysa, and is involved in the regulation of the renal and cardiovascular systems. In mammals, it is involved in the regulation of the cardiovascular system.
-----------------------------------------------------------------------------------------------------------
A major international review of a peptide originally found in fish that could be used in the battle against cardiovascular disease has been published.
Professor David Lambert from the University of Leicester's Department of Cardiovascular Sciences contributed to the review, which has been largely written by the International Union of Basic and Clinical Pharmacology (IUPHAR) subcommittee, to pull together the vast literature on Urotensin II (UII), a peptide first isolated from teleost fish.
UII activates a G protein-coupled receptor called UT to modulate a number of signalling pathways including intracellular Calcium. Interestingly, the peptide can constrict some blood vessels yet dilate others.
The review, which is published in the high impact journal Pharmacological Reviews, has shown that UII can modulate a vast array of biologic activities encompassing the cardiovascular system, kidneys and central nervous system.
Professor Lambert said: "We have been working on this exciting peptide for a number of years; it exhibits a very interesting pharmacological profile. Design and evaluation of small molecule drugs has potential for use in the treatment of several cardiovascular diseases."
